Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 62 | 3,374 | 30% |
| 2020 | 49 | 2,945 | 33% |
| 2021 | 59 |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 41% of the cases CMS names in Illinois; 38 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 754 | 159,886−2.7%/yr | −2.7%/yr | 119.61.1× | 31% | 174,100 in 2030+1.4%/yr |
| ERCP & endoscopic ultrasound |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
| 2024 |
| 5,581 |
| 47% |
| 2025 est. | ≈ 7,000 | – |
| 2026 est. | ≈ 7,680 | – |
| 3,636 |
| 37% |
| 2022 | 60 | 3,878 | 42% |
| 2023 | 72 | 4,594 | 45% |
| 2024 | 82 | 5,581 | 47% |
| 2025 from claims | – | 7,001 6,425–7,407 | 48% |
| 2026 forecast | – | 7,684 6,761–8,867 | 48% |
| 2027 forecast | – | 8,361 7,147–9,963 | 48% |
| 2028 forecast | – | 9,095 7,589–11,137 | 49% |
| 2029 forecast | – | 9,893 8,080–12,407 | 50% |
| 2030 forecast | – | 10,760 8,620–13,789 | 50% |
In 2025, 15% inpatient hospital, 85% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~7,700 | ~1,100 | ~6,600 |
| 2027 · ~8,400 | ~1,100 | ~7,200 |
| 2028 · ~9,100 | ~1,200 | ~7,900 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 13% (15% in 2025), hospital outpatient about 87% (85% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +5.4%/yr |
| 4.0 |
| 0% |
| 4,650 in 2030+9%/yr |
| Michigan | 41 | 2,711−0.1%/yr | −0.1%/yr | 3.3 | 0% | 4,390 in 2030+8.4%/yr |
| Missouri | 36 | 2,414−2.3%/yr | −2.3%/yr | 3.9 | 2% | 2,900 in 2030+3.1%/yr |
| Wisconsin | 40 | 2,262+6.8%/yr | +6.8%/yr | 4.1 | 1% | 4,120 in 2030+11%/yr |
| Minnesota | 28 | 1,774+6.4%/yr | +6.4%/yr | 4.0 | 0% | 3,640 in 2030+13%/yr |
| Kansas | 20 | 1,248+4.7%/yr | +4.7%/yr | 3.1 | 0% | 2,190 in 2030+9.8%/yr |
| Iowa | 25 | 1,181+6.7%/yr | +6.7%/yr | 2.7 | 0% | 2,360 in 2030+12%/yr |
| Nebraska | 19 | 940+6.3%/yr | +6.3%/yr | 3.6 | 0% | 1,420 in 2030+7.1%/yr |
| North Dakota | 6 | 329+11%/yr | +11%/yr | 3.3 | 0% | 750 in 2030+15%/yr |
| South Dakota | 8 | 310+7.1%/yr | +7.1%/yr | 2.4 | 0% | 620 in 2030+12%/yr |
| 80 |
| 5,038−0.4%/yr |
| −0.4%/yr |
| 3.70.9× |
| 1% |
| 6,770 in 2030+5.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcresta Therapeutics leads with 50% of company spending on these surgeons in 2025, +39 pts on 2024.
In 2025, 21 companies reported engagement with Illinois’s surgeons worth $924K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.